Human African trypanosomiasis of the CNS: current issues and challenges
- 15 February 2004
- journal article
- review article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 113 (4) , 496-504
Abstract
Human African trypanosomiasis (HAT), also known as sleeping sickness, is a major cause of mortality and morbidity in sub-Saharan Africa. Current therapy with melarsoprol for CNS HAT has unacceptable side-effects with an overall mortality of 5%. This review discusses the issues of diagnosis and staging of CNS disease, its neuropathogenesis, and the possibility of new therapies for treating late-stage disease.Keywords
This publication has 51 references indexed in Scilit:
- Intrathecal Immune Response Pattern for Improved Diagnosis of Central Nervous System Involvement in TrypanosomiasisThe Journal of Infectious Diseases, 2003
- The role of the polyamine inhibitor ef lornithine in the neuropathogenesis of experimental murine African trypanosomiasisNeuropathology and Applied Neurobiology, 1997
- Trypanosoma brucei and the nervous systemTrends in Neurosciences, 1994
- Gambiense trypanosomiasis: frequency of, and risk factors for, failure of melarsoprol therapyTransactions of the Royal Society of Tropical Medicine and Hygiene, 1994
- CD8 is critically involved in lymphocyte activation by a T. brucei brucei-released moleculeCell, 1993
- The use of azathioprine to ameliorate post-treatment encephalopathy associated with African trypanosomiasisNeuropathology and Applied Neurobiology, 1992
- Subcurative chemotherapy and fatal post-treatment reactive encephalopathies in African trypanosomiasisThe Lancet, 1992
- Neurobiology of sleeping sicknessParasitology Today, 1989
- TRIAL OF PREDNISOLONE FOR PREVENTION OF MELARSOPROL-INDUCED ENCEPHALOPATHY IN GAMBIENSE SLEEPING SICKNESSThe Lancet, 1989
- Immune Complexes in Serum and in Cerebrospinal Fluid in African TrypanosomiasisJournal of Clinical Investigation, 1981